Articles tagged with Weight Loss
A recent study by University of Missouri researcher Mansoo Yu found that online weight loss interventions with counseling and social support are effective for middle-aged adults with obesity. The study identified two key features: professional health coaching and access to social support from other users, which led to significant long-...
A study from Dana-Farber Cancer Institute found that unintentional weight loss is associated with an increased risk of cancer diagnosis within the coming year. The research suggests that patients experiencing unexpected weight loss should see their doctor to consider possible causes, including cancer. Healthy weight loss can come from ...
A study of 157,000 participants found that those with recent weight loss were more likely to be diagnosed with cancer within the next 12 months. Cancer of the upper gastrointestinal tract was most commonly associated with recent weight loss.
A new study found that only 6% of people with type 2 diabetes achieved diabetes remission solely through weight loss by about eight years after diagnosis. People who initially lost a significant amount of weight in the first year were more likely to achieve sustained remission.
Participants with diabetes remission had a 33% lower rate of CKD and a 40% lower rate of CVD compared to those without remission. The magnitude of risk reduction was greatest for participants with longer-term remission.
Researchers found that participants who achieved diabetes remission through weight loss had a 40% lower rate of cardiovascular disease and 33% lower rate of chronic kidney disease. The study, led by Professor Edward Gregg, monitored over 5,000 patients for 12 years.
A recent meta-analysis published in PLOS ONE found that dancing is a highly effective intervention for reducing body fat in overweight and obese individuals. The study analyzed data from various dance interventions and concluded that they can lead to significant weight loss and fat reduction.
A meta-analysis of 90 studies found that adolescents use nonprescription weight-loss products excessively, with girls being more affected. The study highlights the need for interventions to reduce this behavior and mitigate potential long-term health consequences.
A review of over 90 studies found that 5.5% of adolescents globally have used non-prescription weight loss products, while 2% do so in the previous week. Ineffective treatments can lead to long-term health consequences, according to the study.
A study of 25 obese Chinese individuals reveals that intermittent energy restriction (IER) alters the gut microbiome and brain activity, leading to significant weight loss and reductions in obesity-related comorbidities. The changes are coupled over time, suggesting a complex relationship between the gut microbiome and brain.
A diabetes drug called dulaglutide may significantly lower a woman's risk of substantial weight gain after giving up smoking. In contrast to men, women are five times as likely to experience substantial weight gain after stopping smoking, according to the study.
A new poll found that 83% of older adults believe health insurers should cover medications to help people with obesity manage their weight. Nearly as many, 76%, also believe Medicare should cover these drugs, which are currently not covered under law.
A new study finds that a hormone produced by the fetus and a mother's sensitivity to it are the causes behind nausea and vomiting during pregnancy. Lowering GDF15 levels or pre-exposing women to the hormone may mitigate symptoms, providing potential ways to prevent extreme forms of pregnancy sickness.
A BMJ investigation reveals lax regulation of prescription-only weight loss drug adverts in the UK, leaving patients vulnerable to potential harms. The Medicines and Healthcare products Regulatory Agency (MHRA) has not issued a single sanction for prescription drugs in five years.
A Northwestern University study found that nearly two-thirds of patients discontinue or change their medication within a year, highlighting the need for better understanding of barriers to treatment adherence. The high discontinuation rate for GLP-1 RAs may be due to gastrointestinal side effects.
A phase 3 trial found that tirzepatide promotes additional weight loss and preserves metabolic health when continued, but discontinuation leads to significant weight regain. Researchers suggest chronic treatment may be necessary for sustained weight loss and improved cardiometabolic risk factors.
Continued treatment with tirzepatide maintained and augmented initial weight reduction in adults with obesity. Withdrawing tirzepatide led to substantial regain of lost weight in a randomized clinical trial involving 670 participants.
Research suggests that anti-obesity medications can lower the risk of premature death in people with knee or hip osteoarthritis, particularly those who experience a slow-to-moderate rate of weight loss. Studies show a 28% lower risk of death for these individuals compared to those with no weight loss.
Women who underwent bariatric surgery had lower pregnancy weight gain compared to controls with similar early pregnancy characteristics. The study found no difference in weight gain based on surgical procedure or surgery-to-conception interval, but suggested a potential benefit for women with shorter intervals.
The UTHealth Houston School of Public Health offers a 12-month lifestyle program combining evidence-based nutrition education with culinary learning to support behavior change. Participants will attend in-person and virtual classes, including hands-on cooking lessons, physical activity guidance, and mindfulness education.
Replacing animal products with plant-based foods leads to significant weight loss, reduced cholesterol and fat intake, and increased fiber consumption among overweight adults. A new analysis found that a vegan diet rich in fruits, vegetables, grains, and beans results in an average weight loss of about 13 pounds.
Researchers aim to optimize digital weight-loss programs for rural populations by adding human components, such as weekly group video sessions and individual coaching calls. The goal is to help residents manage their weight and fight the obesity epidemic in areas with limited access to in-person programs.
A 20% reduction in major adverse cardiovascular events has been observed for patients with obesity but no history of diabetes taking semaglutide. This study marks a significant milestone, demonstrating the cardiovascular benefits of semaglutide beyond its weight loss effects.
Researchers found that people with overweight or obesity who took semaglutide for over 3 years had a 20% lower risk of heart attack, stroke, or death from cardiovascular disease. The study showed significant weight loss and improved cardiovascular outcomes in adults without diabetes.
A recent clinical trial found that semaglutide significantly reduced cardiovascular events in adults with overweight or obesity who do not have diabetes. The medication was shown to lower the risk of death from cardiovascular causes, nonfatal heart attacks, and strokes by 20% compared to placebo.
Researchers from Helmholtz Munich discovered that GIP decreases body weight by interacting with specific inhibitory neurons in the brain, offering a revolutionary approach to patients worldwide. The study reveals the underlying molecular mechanisms of GIPR:GLP-1R co-agonists and their potential as next-generation anti-obesity drugs.
The American Gastroenterological Association suggests a balanced approach when treating patients on GLP-1 RAs undergoing endoscopic procedures. AGA recommends proceeding with the procedure as planned for patients who followed standard pre-procedure fasting instructions and do not have symptoms suggesting retained gastric contents.
A study found that physicians who presented treatments for obesity as good news and an opportunity were more successful in helping patients lose weight. Patients who received counseling with a positive and optimistic tone had significantly higher weight loss outcomes compared to those who received neutral or negative advice.
A large-scale study found that metformin can reduce weight gain and increase adherence to treatment in youth with bipolar disorder. The medication, typically used for Type 2 diabetes, was effective in preventing weight gain and showed promise as a potential solution to this common side effect of SGAs.
A six-month randomized clinical trial involving 75 adults with type 2 diabetes found that time-restricted eating was effective for weight loss. This novel dietary approach lowered hemoglobin A1c levels without calorie counting, offering potential for improved blood sugar management and overall health.
A new study published in JAMA Network Open found time-restricted eating to be safe and effective for people with Type 2 diabetes, helping them lose weight and control blood sugar levels. Participants who followed the time-restricted eating plan had an easier time sticking to it than those on a calorie-reduced diet.
The SURMOUNT-3 study demonstrated a significant weight loss of 24.3% in participants administered tirzepatide, compared to 2.5% for placebo. The study also showed improvements in multiple health measures, including waist circumference and blood sugar levels.
A new UConn study examined the effect of couples on each other's 'grit' and self-control, key ingredients for weight management. Researchers found that couples did not influence each other's self-control or grit levels, but rather these traits were malleable through behavioral interventions.
A study found that the host's immune response to Trypanosoma brucei infection triggers lipolysis, leading to weight loss and a protective effect against disease progression. This discovery opens up new treatment strategies targeting the infection in adipose tissue.
A new study found that pre-pregnancy obesity is a primary driver of future cardiovascular disease risk, rather than pregnancy complications. The research followed 4,216 individuals from early pregnancy to postpartum and found those with overweight or obese BMI had a higher risk of developing hypertensive disorders during pregnancy.
The study found that glucagon-like peptide-1 agonists are associated with a higher risk of pancreatitis, gastroparesis, and bowel obstruction compared to bupropion-naltrexone. Patients considering weight loss medication should be aware of these potential risks due to the drugs' wide use.
A large epidemiological study found a higher incidence of stomach paralysis, pancreatitis, and bowel obstruction in patients taking GLP-1 agonist medications for weight loss. The study, published in JAMA, highlights the need for updated warning labels to inform patients of these potential risks.
Research reveals that low muscle mass is associated with a two-fold risk of death from cardiovascular disease in individuals with diabetes. The study found that body composition, not just weight loss, plays a crucial role in managing weight in people with diabetes.
A UCLA-led team has discovered the nerve supply that activates brown adipose tissue, a potential key to treating obesity. The study found nerve branches in all eight cadavers dissected, which may lead to using nerves to stimulate BAT activity for weight loss.
A recent study demonstrated that lasting remission of type 2 diabetes is feasible in the real-world setting through a low-calorie diet and weight loss maintenance. The DiRECT trial showed significant weight loss and remission rates, even after five years, with participants who maintained their weight losing type 2 diabetes permanently.
Researchers at the University of Birmingham found that individuals with fatty liver disease are three times more likely to have a personality disorder than those without. Lifestyle modifications, such as changes in diet and exercise, can prevent disease progression but often fail to be implemented due to mental health factors.
A real-world study of over 23,000 adults with type 2 diabetes found that semaglutide significantly improved blood sugar control and weight loss for up to 3 years. The study showed that patients who had never taken a GLP-1 RA or those with higher adherence achieved more pronounced reductions in blood sugar levels and weight loss.
A new exercise-mimicking drug, SLU-PP-332, has shown promising results in obese mice, leading to weight loss and increased muscle activity without increasing physical activity. The drug works by boosting a natural metabolic pathway, making the body act like it is training for a marathon, resulting in faster metabolism of fat.
Researchers found a 55% reduction in lymphoma risk and a 40% overall reduction in blood cancer risk among bariatric surgery patients. Women with high blood sugar at the start of the study benefited most from the surgery.
Researchers found that almond-supplemented diets resulted in significant weight loss and improved cardiometabolic outcomes. The study demonstrated the benefits of nuts as part of a balanced weight loss diet, with almonds providing unsaturated fats that can improve blood cholesterol levels and contribute to a healthy heart.
A randomized controlled trial found that high-protein and normal-protein diets were both effective in improving glucose control, weight loss, and body composition in adults with Type 2 diabetes. The study suggests that individuals can choose a dietary pattern that suits their preferences while still achieving significant health benefits.
Women with polycystic ovary syndrome (PCOS) who follow a keto diet for at least 45 days may experience significant weight loss and improvements in reproductive hormone levels. Lower testosterone levels can also help reduce excess hair growth and other symptoms associated with PCOS.
Researchers have identified a cluster of neurons in the hypothalamus called GABRA5 that regulates energy expenditure. Astrocytes control this cluster, producing tonic GABA that inhibits it, leading to weight gain.
Women who maintained a stable weight were 1.2 to 2 times more likely to achieve exceptional longevity compared to those who lost 5% or more, with a 51% lower survival rate at age 90. Stable weight is associated with increased longevity in older women.
Researchers developed a liver-targeting drug that reversed obesity and lowered cholesterol in obese mice by delivering the drug via nanogel. The treatment, which was administered intraperitoneally, effectively normalized weight and reduced cholesterol levels despite continued high-fat diet consumption.
A new study from the University of Copenhagen reveals that GDF15 improves insulin sensitivity in rodents, particularly in their liver and fatty tissue. This finding raises interesting perspectives for treating type 2 diabetes and high blood pressure, as increased insulin sensitivity is a critical indicator of health.
A pilot study led by George Mason University's Michael Bloom explores the impact of PFAS on weight loss in Hispanic children participating in a community-based weight loss intervention. The research aims to quantify associations between PFAS exposure and weight lost, as well as clinical biomarkers.
A new study from Lund University in Sweden found that the biggest metabolic changes following gastric bypass surgery occurred immediately after the procedure. However, one year later, the concentration of metabolites and fats had returned to nearly pre-surgery levels.
Researchers found that both dietary weight loss strategies improved the diversity of the gut microbiome. The study suggests that individuals can choose a strategy that works for them, regardless of its impact on their microbiome. Changes in the microbiome may also affect other body functions.
Researchers found that liraglutide improves associative learning in people with obesity by restoring brain activity to normal-weight levels. The study showed that participants with obesity had reduced ability to associate sensory stimuli and decreased brain activity compared to those with normal weight.
Neuroscientists at Scripps Research have identified a specific cluster of neurons that work as a 'switch' for cold-related food-seeking behavior in mice. The discovery could lead to potential therapeutics for metabolic health and weight loss by targeting this brain circuitry.
A recent study at UC Irvine found that semaglutide medication can lead to significant weight loss and reduce cardiovascular risk in 93 million U.S. adults. The medication may prevent up to 1.5 million heart attacks and strokes over 10 years, resulting in 43 million fewer obese people.
The study of 18.4 million patients indicates a low annual probability of 5% or greater weight loss, but a higher likelihood of BMI reduction to the healthy weight category, especially among those with high initial BMIs.
A randomized clinical trial found that telephone-based cognitive behavioral therapy (tele-CBT) significantly reduced binge eating, emotional eating, and depression/anxiety symptoms in individuals after bariatric surgery. However, short-term weight outcomes were unaffected by tele-CBT.
A world-first study from the University of South Australia exposes the real weight gains of everyday Australians, finding that weight fluctuates throughout the year. The study highlights the importance of targeting temporal hot spots to curb unhealthy weight fluctuations and prevent unwanted weight gain.